Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis
Rashmi Mahajan, Anuj Kumar Tyagi · 2024
Read Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis by Rashmi Mahajan, Anuj Kumar Tyagi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11622454.txt.
Description
Rashmi Mahajan and Anuj Tyagi pool evidence on gene variants that raise liver harm risk during tuberculosis treatment, in a review from 2024. Liver injury is a serious side effect of anti-tuberculosis drugs. A gene that processes such drugs comes in fast and slow forms, and slow forms may let toxins build up.
They gathered twenty-four studies from major databases and pooled risk by gene form, with splits by ancestry, regimen, and testing method. Slow acetylators faced well over double the odds of liver harm versus other types. Three slow genotype pairs stood out as most strongly linked. The authors back gene screening to guide dosing.
Catalog record
| CREATOR | Rashmi Mahajan, Anuj Kumar Tyagi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |